Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medroxyprogesterone in acute COPD exacerbation requiring NIV
IRCT20210730052016N2Phase 3Recruiting
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of medroxyprogesterone acetate in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Arterial pH, Partial pressure of carbon dioxide and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
medroxyprogesterone acetate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20210730052016N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210730052016N2.